Dynavax Technologies | DVAX - Ebitda



Dynavax Technologies reported $-21594000 in EBITDA for its fiscal quarter ending in March of 2025.


Ebitda Change Date
AbbVie USD 4.4B 2.52B Mar/2025
Adma Biologics USD 43.99M 3.58M Jun/2025
Amgen USD 3.6B 147M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Dynavax Technologies USD -21594000 22.03M Mar/2025
Gilead Sciences USD 3.4B 797M Jun/2025
Glaxosmithkline GBP 3.23B 1.54B Jun/2025
Merck USD 7.74B 625M Mar/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
Novartis USD 6.17B 339M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
TG Therapeutics USD 12.28M 17.68M Mar/2025
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025